Deal overview
| Target | DAIICHI SANKYO (CERTAIN RIGHTS TO TRASTUZUMAB DERUXTECAN) |
|---|---|
| Bidder | ASTRAZENECA PLC |
| Price | £60.00 Full version or £25.00 Light version |
| Publication Date | Mar 28, 2019 |
| Abstract | On 28 March 2019[+], it was announced that the UK quoted pharmaceuticals group AstraZeneca Plc, had entered into a global development and commercialisation collaboration agreement with the Japanese quoted pharmaceuticals group Daiichi Sankyo Company, Limited ("Daiichi Sankyo") for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate ("ADC") and potential ... |
| Number of pages (Full version) | 6 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
Search for Deals
Search over 70 million deal reports on more than 550,000 public and private companies. (copy)
©2020 M&A Monitor Limited
